Browse the evidence

Obesity-associated gonadal dysfunction is highly prevalent in severely obese patients, affecting 36% of women (PCOS) and 64% of men (MOSH).

If you are severely obese, you are at high risk for hormonal reproductive issues. About 1 in 3 severely obese women has PCOS, and nearly 2 in 3 severely obese men has low testosterone (MOSH). Screening for these conditions is recommended during initial diagnostic workup for severe obesity.

Gait speed is a critical predictor of survival, disability, and mobility loss in older adults, with a speed of approximately 0.8 m/s indicating median life expectancy.

Monitor your walking speed. If you walk slower than 0.8 meters per second (roughly 1.8 mph), you are at higher risk for early mortality and disability. Use this as a signal to engage in regular physical activity, particularly strength and balance training, to preserve your mobility and longevity.

Mitochondrial impairment accelerates epigenetic aging, while enhancing mitochondrial biogenesis slows it, establishing a direct link between mitochondrial function and the rate of epigenetic aging.

Mitochondrial health is a key driver of epigenetic aging. Impairing mitochondria accelerates the epigenetic clock, while boosting mitochondrial biogenesis slows it. This suggests that interventions supporting mitochondrial function (like exercise or specific nutrients) may slow epigenetic aging, independent of DNA repair or telomere length.

Women with diabetes face a 58% greater risk of coronary heart disease (CHD) mortality and a 13% greater risk of all-cause mortality compared to men with diabetes, indicating a significant sex-specific disparity in cardiovascular outcomes.

If you are a woman with diabetes, your risk of dying from heart disease is significantly higher than a man with diabetes. This means you should not just manage your blood sugar, but actively prioritize cardiovascular health with your doctor, potentially requiring more aggressive monitoring or prevention strategies than standard male-centric guidelines might suggest.

Visceral adipose tissue (VAT) and epicardial adipose tissue (EAT) accumulation is a primary driver of cardiovascular injury in obesity and diabetes, independent of overall body mass index (BMI), through the release of pro-inflammatory factors and free fatty acids.

For individuals with obesity or Type-2 Diabetes, focusing solely on BMI is insufficient for assessing heart disease risk. Visceral and epicardial fat are more dangerous indicators. Reducing these specific fat depots through lifestyle changes or medication is crucial for preventing heart failure and other cardiovascular injuries.

The doubly labelled water (DLW) method is the gold standard for measuring total energy expenditure in free-living humans because it accurately captures activity energy expenditure without interfering with subject behavior.

If you need to know your true energy expenditure in daily life, self-reports and most wearables are unreliable. The doubly labelled water method is the only validated way to measure this accurately without restricting your normal activities, though it is primarily a research tool due to cost and complexity.

Moderate or non-excessive alcohol consumption, along with above-median fruit and vegetable intake, are key components driving the mortality-reducing association of the Mediterranean Diet.

To maximize longevity benefits, prioritize high intake of fruits and vegetables, include moderate alcohol if you already drink, and limit meat intake, as higher meat consumption was associated with increased mortality risk in this analysis.

Metformin administration (1,700 mg/day) blunts gains in lean body mass and thigh muscle mass in older adults undergoing progressive resistance training.

If you are over 65 and taking metformin, expect less muscle gain from resistance training compared to someone not taking it. This is likely due to how metformin affects cellular signaling (mTOR/AMPK). Do not stop your medication without medical advice, but adjust your expectations for muscle growth.

Once-weekly subcutaneous semaglutide 2.4 mg reduces the risk of major kidney composite endpoints (including macroalbuminuria and persistent eGFR decline) in patients with overweight/obesity and established cardiovascular disease, regardless of diabetes status.

If you have obesity and heart disease but no diabetes, semaglutide 2.4mg weekly offers significant kidney protection. It reduces the risk of serious kidney events like needing dialysis or developing heavy protein in the urine. While there is a temporary initial dip in kidney filtration numbers, long-term outcomes are better than placebo. This is a standard-of-care option for kidney risk reduction in this specific high-risk group.

Semaglutide 2.4 mg slows the rate of eGFR decline and reduces albuminuria (UACR) in patients with overweight/obesity, with greater benefits observed in those with baseline eGFR <60 ml/min/1.73m².

For patients with existing kidney impairment (eGFR <60), semaglutide not only slows further decline but may actually improve eGFR readings compared to placebo. It also significantly reduces albuminuria (protein in urine), a key marker of kidney stress. This benefit is consistent across subgroups.

Macrofungi are a source of high-quality protein, unsaturated fatty acids, and minerals, making them a low-calorie functional food suitable for general health.

Eat mushrooms regularly as a source of protein and fiber. They are low in calories but nutrient-dense, making them a good addition to a balanced diet.

Bariatric surgery (RYGB/VSG) provides superior sustained weight loss (13-27%) and T2D remission compared to pharmacological interventions, largely driven by endocrine changes rather than just mechanical restriction.

Bariatric surgery (like gastric bypass) is currently the most effective treatment for obesity, achieving 13-27% sustained weight loss and often curing type 2 diabetes. Its success is driven by hormonal changes (increased GLP-1/PYY) rather than just stomach size reduction. However, due to its invasive nature, it is reserved for extreme cases, driving the need for drugs that can mimic these hormonal effects.

High body mass index (BMI > 25 kg/m²) is a major global health risk factor that has caused a more than 2.5-fold increase in global deaths and disability-adjusted life years (DALYs) between 1990 and 2021, with cardiovascular diseases and diabetes being the leading causes of this burden.

High body mass index (BMI) is a major, modifiable risk factor for serious diseases like heart disease, diabetes, and kidney disease. The global burden of disease from high BMI has more than doubled in 30 years. To protect your health, it is crucial to monitor your BMI and work towards maintaining a healthy weight through sustainable lifestyle changes, as high BMI significantly increases your risk of premature death and disability.

High genetic risk for obesity (high GSBMI) is significantly attenuated by frequent alcohol consumption, meaning daily drinkers experience a much smaller genetic effect on BMI compared to non-drinkers.

If you have a high genetic predisposition to obesity, your drinking habits matter more for your weight than the total amount you drink. Specifically, drinking alcohol frequently (daily) appears to blunt the genetic effect on BMI compared to not drinking or drinking rarely. However, this does not mean alcohol is 'good' for weight loss; it is a specific gene-environment interaction where the genetic risk manifests differently.

A slower usual walking pace significantly amplifies the genetic effect on BMI, with the genetic score effect being 2.5 times higher in slow walkers compared to brisk walkers.

If you are genetically prone to obesity, how fast you walk matters. Walking at a brisk pace significantly reduces the genetic impact on your BMI compared to walking slowly. Increasing your daily walking speed is a low-barrier way to mitigate genetic risk.

Sarcopenia is defined by the loss of muscle mass, strength, and physical function, and its prevalence varies significantly depending on the definition used.

Sarcopenia is a serious condition involving loss of muscle mass, strength, and function. Its diagnosis depends on the specific criteria used, so prevalence rates vary widely.

Statins reduce cardiovascular events and inflammatory markers (CRP) but may increase the risk of new-onset diabetes, indicating a trade-off between cardiovascular protection and glycemic control.

Statins are highly effective at preventing heart attacks and strokes, even in people with normal cholesterol but high inflammation. However, they can slightly increase the risk of developing diabetes. For most people with cardiovascular risk, the heart protection outweighs this risk. Monitor your blood sugar if you start statins.

Melatonin regulates circadian rhythms and sleep-wake cycles by acting on the suprachiasmatic nucleus (SCN) and pineal gland, with secretion peaking at night.

Melatonin is your body's natural signal for darkness and sleep. It is produced by the pineal gland in response to darkness, peaks at night, and helps regulate your sleep-wake cycle. Exposure to light at night suppresses this natural production.

Higher body mass index (BMI), abdominal fatness (waist circumference), and total body fat mass are associated with a significantly increased risk of developing atrial fibrillation, with risk increasing non-linearly at higher BMI levels.

Maintain a healthy body weight and minimize abdominal fat to lower your risk of atrial fibrillation. This risk increases even within the 'normal' BMI range (starting around 22) and is strongly linked to waist size and total body fat mass, not just obesity. Focus on keeping your waist circumference low and overall fat mass in check, as these are significant, modifiable risk factors for heart rhythm disorders.

Tirzepatide treatment is associated with a higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting) compared to placebo and insulin, and slightly higher than GLP-1 RAs, though serious adverse events are not significantly different from placebo.

Expect gastrointestinal side effects like nausea, diarrhea, or vomiting, especially when starting or increasing the dose. These are usually mild and go away. Serious side effects (like pancreatitis or heart issues) did not show a statistically significant increase compared to placebo in this analysis. Monitor your symptoms and report severe or persistent issues to your doctor.

Tirzepatide use is associated with a significantly higher incidence of gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, compared to placebo, although serious adverse event rates remain comparable.

Expect gastrointestinal side effects when starting tirzepatide. Nausea, vomiting, and diarrhea are significantly more common than with a placebo, particularly when starting or increasing the dose. However, these are typically mild to moderate and do not appear to increase the risk of serious health events. Most patients tolerate the medication well enough to continue treatment, which is necessary to achieve the significant weight loss benefits.

Fad diets, supplements, and unproven therapies (e.g., phytotherapics, probiotics for weight loss) are ineffective and potentially harmful for obesity treatment.

Avoid fad diets and unproven supplements (phytotherapics, probiotics, caffeine supplements) for weight loss. They are ineffective and may be harmful. Focus on evidence-based strategies like calorie restriction and behavioral changes.

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, constipation, dyspepsia) compared to placebo, which increases with dose and leads to higher discontinuation rates, but does not increase the risk of serious adverse events.

Tirzepatide is more likely to cause stomach issues like nausea and vomiting than a placebo, and these side effects are more common at higher doses. This can lead to some people stopping the medication, but it does not increase the risk of serious health problems. Managing these side effects is key to staying on the treatment.

Tirzepatide use is associated with a significantly higher incidence of adverse reactions, particularly nausea and diarrhea, which are dose-dependent and increase with higher doses (15mg).

Be prepared for potential side effects like nausea and diarrhea when starting Tirzepatide. These side effects are more likely at higher doses (15mg) and may decrease over time as your body adjusts. Most people tolerate the medication well, but it's important to discuss these potential side effects with your doctor.